Skip to content
10-Q

Quarterly Report

Contineum Therapeutics, Inc. CTNM

0001437749-25-016835

← back to feed
Filed
May 14, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 9, 2025 25.87M sh
Cash And Equivalents Q1 2025 · Mar 31, 2025 $22.47M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $21.94M
Current Liabilities Q1 2025 · Mar 31, 2025 $8.95M
Current Liabilities Q1 2025 · Dec 31, 2024 $9.97M
Total Liabilities Q1 2025 · Mar 31, 2025 $13.5M
Total Liabilities Q1 2025 · Dec 31, 2024 $14.78M
Current Assets Q1 2025 · Mar 31, 2025 $192.13M
Current Assets Q1 2025 · Dec 31, 2024 $206.39M
Total Assets Q1 2025 · Mar 31, 2025 $198.26M
Total Assets Q1 2025 · Dec 31, 2024 $212.85M
Capex Q1 2025 · Mar 31, 2024 $147K
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$7.98M
Stockholders Equity Q1 2025 · Mar 31, 2024 −$75.63M
Stockholders Equity Q1 2025 · Dec 31, 2023 −$67.94M
Eps Basic Q1 2025 · Mar 31, 2024 −$3.55
Sga Expense Q1 2025 · Mar 31, 2024 $2.15M
Rd Expense Q1 2025 · Mar 31, 2024 $7.78M
Net Income Q1 2025 · Mar 31, 2024 −$8.42M
Operating Income Q1 2025 · Mar 31, 2024 −$9.93M